====== COVID-19 Vaccine Associated Myopericarditis and Perimyocarditis ====== See also: [[covid-19_vaccines:adverse_events:myocarditis|CoVid-19 Vaccine Associated Myocarditis]] and [[covid-19_vaccines:adverse_events:pericarditis|CoVid-19 Vaccine Associated Pericarditis]] Myopericarditis refers to inflammation of the pericardium and myocarditis. Myopericarditis is sometimes used interchangeably with perimyocarditis. >Myopericarditis is used when there are primarily pericarditis symptoms with evidence of the involvement of the myocardium as evidenced by cardiac biomarker elevation or imaging studies revealing normal wall motion. If there is evidence of regional wall motion abnormalities with reduced ventricular function, the term perimyocarditis has been used. [[https://www.ncbi.nlm.nih.gov/books/NBK534776/|Manda YR, Baradhi KM. Myopericarditis. [Updated 2021 Jul 26]]] ===== Summary from the CDC ===== [[https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-08-30/03-COVID-Su-508.pdf|Myopericarditis following COVID-19 vaccination: Updates from the Vaccine. Adverse Event Reporting System (VAERS). CDC Aug 30, 2021.]] * 2,574 reports of myopericarditis or pericarditis to VAERS (as of August 18, 2021) * 1,903 myopericarditis, 671 pericarditis * Epidemiology of myopericarditis following COVID-19 vaccination similar to previously reported updates * Primarily in younger males, after dose 2 mRNA vaccination, symptom onset clustering within several days of vaccination * Limited follow-up information in VAERS case reports suggests most patients (77%) recovered from symptoms at time of report or follow-up * Observed vs. Expected analysis with VAERS reports * Males: Observed > Expected in age groups through 49 years * Females: Observed > Expected in age groups through 29 years * Enhanced surveillance for myocarditis outcomes after mRNA COVID-19 vaccination in VAERS case reports is ongoing ===== Peer-Reviewed Scientific papers regarding COVID-19 Vaccine Associated Myopericarditis ===== [[https://www.sciencedirect.com/science/article/pii/S002234762100665X|Myopericarditis after Pfizer mRNA COVID-19 vaccination in adolescents ]] [[https://www.sciencedirect.com/science/article/pii/S0022347621007368|Myopericarditis after vaccination with COVID-19 mRNA in adolescents 12 to 18 years of age ]] [[https://www.sciencedirect.com/science/article/pii/S0022347621007496|Important information on myopericarditis after vaccination with Pfizer COVID-19 mRNA in adolescents ]] [[https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab741/6359059|Insights from a murine model of COVID-19 mRNA vaccine-induced myopericarditis: could accidental intravenous injection of a vaccine induce myopericarditis]] [[https://www.sciencedirect.com/science/article/abs/pii/S188558572100133X|Acute myocarditis after administration of BNT162b2 vaccine against COVID-19]] [[https://pubmed.ncbi.nlm.nih.gov/34453510/|Insights from a murine model of myopericarditis induced by COVID-19 mRNA vaccine: could accidental intravenous injection of a vaccine induce myopericarditis]] [[https://www.medrxiv.org/content/10.1101/2021.09.13.21262182v1.full?s=09|COVID-19 mRNA vaccination and development of CMR-confirmed myopericarditis.]] [[https://t.co/j0IEM8cMXI|Intravenous injection of coronavirus disease 2019 (COVID-19) mRNA vaccine can induce acute myopericarditis in a mouse model ]] [[https://pubmed.ncbi.nlm.nih.gov/34133825/|Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report]] [[https://pubmed.ncbi.nlm.nih.gov/34636504/|Report of a case of myopericarditis after vaccination with BNT162b2 COVID-19 mRNA in a young Korean male]] [[https://pubmed.ncbi.nlm.nih.gov/34228985/|Myopericarditis after Pfizer messenger ribonucleic acid coronavirus coronavirus disease vaccine in adolescents]] [[https://pubmed.ncbi.nlm.nih.gov/34589238/|Acute myopericarditis after COVID-19 vaccine in adolescents]] [[https://www.ncbi.nlm.nih.gov/pubmed/34889875|Population-based Incidence of Myopericarditis After COVID-19 Vaccination in Danish Adolescents. Pediatr Infect Dis J, 41(1), e25-e28. doi:10.1097/INF.0000000000003389]] . [[https://www.ncbi.nlm.nih.gov/pubmed/34228985|Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents. J Pediatr, 238, 317-320. doi:10.1016/j.jpeds.2021.06.083]] [[https://www.ncbi.nlm.nih.gov/pubmed/34952008|mRNA Coronavirus-19 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study. J Pediatr. doi:10.1016/j.jpeds.2021.12.025. [[https://www.ncbi.nlm.nih.gov/pubmed/34332972|Important Insights into Myopericarditis after the Pfizer mRNA COVID-19 Vaccination in Adolescents. J Pediatr, 238, 5. doi:10.1016/j.jpeds.2021.07.057]] [[https://www.ncbi.nlm.nih.gov/pubmed/34133825|Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: A case report. Acad Emerg Med, 28(8), 918-921. doi:10.1111/acem.14322]] [[https://www.ncbi.nlm.nih.gov/pubmed/34904134|Recurrence of myopericarditis following mRNA COVID-19 vaccination in a male adolescent. CJC Open. doi:10.1016/j.cjco.2021.12.002]] [[https://www.ncbi.nlm.nih.gov/pubmed/34339728|Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age. J Pediatr, 238, 26-32 e21. doi:10.1016/j.jpeds.2021.07.044]] [[https://www.ncbi.nlm.nih.gov/pubmed/33406694| Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. Vaccines (Basel), 9(1). doi:10.3390/vaccines9010019]] [[https://pubmed.ncbi.nlm.nih.gov/34133825/|Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination: Case report]] [[https://journals.lww.com/pidj/Abstract/9000/Transient_Cardiac_Injury_in_Adolesce nts_Receiving.95800.aspx|Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine ]] ===== Peer-Reviewed Scientific papers regarding COVID-19 Vaccine Associated Perimyocarditis ===== [[https://academic.oup.com/jpids/advance-article/doi/10.1093/jpids/piab060/6329543|Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine]] [[https://pubmed.ncbi.nlm.nih.gov/34319393/|Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine]] [[https://pubmed.ncbi.nlm.nih.gov/34447639/|Unusual presentation of acute perimyocarditis after modern SARS-COV-2 mRNA-1237 vaccination]] [[https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-021-02183|Perimyocarditis after the first dose of mRNA-1273 SARS-CoV-2 (Modern) mRNA-1273 vaccine in a young healthy male: case report]] [[https://pubmed.ncbi.nlm.nih.gov/34515024/|Acute perimyocarditis after the first dose of COVID-19 mRNA vaccine]] [[https://pubmed.ncbi.nlm.nih.gov/34866957/|Perimyocarditis after vaccination with COVID-19]] [[https://www.ncbi.nlm.nih.gov/pubmed/34866957|Perimyocarditis Following COVID-19 Vaccination. Clin Med Insights Cardiol]] [[https://www.ncbi.nlm.nih.gov/pubmed/34270752]Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents. J Pediatric Infect Dis Soc]] [[https://www.ncbi.nlm.nih.gov/pubmed/34447639Unusual Presentation of Acute Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Vaccination. Cureus]] [[https://www.ncbi.nlm.nih.gov/pubmed/34348657|Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report. BMC Cardiovasc Disord]]